/

Società

GN

Non verificato

GN Corporation Co Ltd

Di cosa scriviamo

6 comunicati stampa

Guarda tutti i comunicati

27/10/2025

Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan

Fonte

GN Corporation Co Ltd

Emittente

1.00

0

31/03/2025

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

Fonte

GN Corporation Co Ltd

Emittente

1.00

0

17/03/2025

Astronauts’ Health During Space Missions: Nichi BRITE and Neu REFIX Beta Glucans Could Benefit by Neutrophil-to-Lymphocyte Ratio, IL-6 Control, the Immune Biomarkers of Aging and Longevity

Fonte

GN Corporation Co Ltd

Emittente

1.00

0

20/09/2024

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

Fonte

GN Corporation Co Ltd

Emittente

1.00

0

10/08/2024

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

Fonte

GN Corporation Co Ltd

Emittente

1.00

0

08/08/2024

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

Fonte

GN Corporation Co Ltd

Emittente

1.00

0

Seguaci

0

Compatibilità

0